Ken Griffin Pds Biotechnology Corp Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 67,900 shares of PDSB stock, worth $109,319. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,900

Previous 8,300 718.07%

Holding current value

$109,319

Previous $13,000 515.38%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.63 - $4.11 $171,529 - $432,507	105,233 Added 91.52%	220,215 $358,000
Q3 2024 Nov 14, 2024	BUY	$2.93 - $4.23 $194,176 - $280,330	66,272 Added 136.05%	114,982 $439,000
Q2 2024 Aug 14, 2024	SELL	$2.55 - $4.02 $6,770 - $10,673	-2,655 Reduced 5.17%	48,710 $142,000
Q1 2024 May 15, 2024	SELL	$3.85 - $6.59 $304,215 - $520,722	-79,017 Reduced 60.6%	51,365 $203,000
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $135,852 - $226,305	34,393 Added 35.83%	130,382 $647,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $216,662 - $288,883	45,138 Added 88.77%	95,989 $484,000
Q2 2023 Aug 14, 2023	SELL	$5.03 - $9.9 $372,501 - $733,154	-74,056 Reduced 59.29%	50,851 $255,000
Q1 2023 May 15, 2023	BUY	$5.68 - $11.99 $554,816 - $1.17 Million	97,679 Added 358.74%	124,907 $768,000
Q4 2022 Feb 14, 2023	SELL	$3.28 - $13.2 $301,087 - $1.21 Million	-91,795 Reduced 77.12%	27,228 $359,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $258,704 - $504,343	87,106 Added 272.91%	119,023 $353,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

8.16M

Call Options Held

151K

Put Options Held

1.2K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $45.8M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account